{"id":"standard-darolutamide","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Hypertension"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in a decrease in the growth and spread of prostate cancer cells. By blocking the effects of androgens, darolutamide can help slow the progression of the disease.","oneSentence":"Darolutamide is a nonsteroidal antiandrogen that competitively inhibits the action of androgens, such as testosterone and dihydrotestosterone, at their receptor sites in various tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:13.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer"}]},"trialDetails":[{"nctId":"NCT06592924","phase":"PHASE3","title":"Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2025-05-28","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":830},{"nctId":"NCT06661122","phase":"","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-11-18","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis","enrollment":100},{"nctId":"NCT05348876","phase":"PHASE4","title":"A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-08-03","conditions":"Non-metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer","enrollment":168},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT06724159","phase":"","title":"Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.","status":"RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2024-12-13","conditions":"Genitourinary Cancers","enrollment":500},{"nctId":"NCT05683964","phase":"EARLY_PHASE1","title":"Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-01-19","conditions":"Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":9},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT07244341","phase":"PHASE1","title":"A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-12-03","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT04946370","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-08-12","conditions":"Prostate Cancer","enrollment":37},{"nctId":"NCT07344779","phase":"","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-17","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1600},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":25},{"nctId":"NCT06010914","phase":"","title":"A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-10-09","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":100},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT06594926","phase":"PHASE2","title":"Working Out M0 Bipolar Androgen Therapy","status":"RECRUITING","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2024-08-14","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT07181122","phase":"","title":"Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Ankara Etlik City Hospital","startDate":"2025-10-22","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":102},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT05346848","phase":"PHASE2","title":"Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2023-02-24","conditions":"Prostate Cancer","enrollment":62},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT06401980","phase":"PHASE2","title":"Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-22","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":162},{"nctId":"NCT06625970","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-04-10","conditions":"High Risk Prostate Carcinoma, Prostate Cancer","enrollment":700},{"nctId":"NCT05171387","phase":"PHASE2","title":"Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-11-30","conditions":"Prostate Cancer","enrollment":78},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT05676203","phase":"PHASE3","title":"A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jena University Hospital","startDate":"2023-05-16","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":250},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT04916613","phase":"PHASE3","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-04-19","conditions":"Prostate Cancer Metastatic","enrollment":300},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT06177015","phase":"PHASE3","title":"Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-11","conditions":"Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy","enrollment":200},{"nctId":"NCT05771896","phase":"PHASE3","title":"Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC","status":"WITHDRAWN","sponsor":"GenesisCare USA","startDate":"2023-09","conditions":"Metastatic Prostate Cancer","enrollment":""},{"nctId":"NCT04136353","phase":"PHASE3","title":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2020-03-31","conditions":"Prostate Cancer","enrollment":1100},{"nctId":"NCT05209243","phase":"NA","title":"START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-01-26","conditions":"Prostate Cancer, Stereotactic Body Radiation Therapy","enrollment":266}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":100,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard Darolutamide","genericName":"Standard Darolutamide","companyName":"Jena University Hospital","companyId":"jena-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darolutamide is a nonsteroidal antiandrogen that competitively inhibits the action of androgens, such as testosterone and dihydrotestosterone, at their receptor sites in various tissues. Used for Metastatic castration-resistant prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}